These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 30660034)

  • 1. Determination of total and unbound ribociclib in human plasma and brain tumor tissues using liquid chromatography coupled with tandem mass spectrometry.
    Bao X; Wu J; Sanai N; Li J
    J Pharm Biomed Anal; 2019 Mar; 166():197-204. PubMed ID: 30660034
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An aqueous normal-phase chromatography coupled with tandem mass spectrometry method for determining unbound brain-to-plasma concentration ratio of AZD1775, a Wee1 kinase inhibitor, in patients with glioblastoma.
    Wu J; Sanai N; Bao X; LoRusso P; Li J
    J Chromatogr B Analyt Technol Biomed Life Sci; 2016 Aug; 1028():25-32. PubMed ID: 27318641
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development and validation of LC-MS/MS methods for the measurement of ribociclib, a CDK4/6 inhibitor, in mouse plasma and Ringer's solution and its application to a cerebral microdialysis study.
    Kala A; Patel YT; Davis A; Stewart CF
    J Chromatogr B Analyt Technol Biomed Life Sci; 2017 Jul; 1057():110-117. PubMed ID: 28521250
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic Monitoring of Palbociclib, Ribociclib, Abemaciclib, M2, M20, and Letrozole in Human Plasma: A Novel LC-MS/MS Method.
    Posocco B; Zanchetta M; Orleni M; Gagno S; Montico M; Peruzzi E; Roncato R; Gerratana L; Corsetti S; Puglisi F; Toffoli G
    Ther Drug Monit; 2024 Aug; 46(4):485-493. PubMed ID: 38366332
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development and validation of a bioanalytical method for the quantification of the CDK4/6 inhibitors abemaciclib, palbociclib, and ribociclib in human and mouse matrices using liquid chromatography-tandem mass spectrometry.
    Martínez-Chávez A; Rosing H; Hillebrand M; Tibben M; Schinkel AH; Beijnen JH
    Anal Bioanal Chem; 2019 Aug; 411(20):5331-5345. PubMed ID: 31209549
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development and validation of a liquid chromatography coupled with tandem mass spectrometry method for determining total and unbound pamiparib in human plasma and brain tumors.
    Jiang J; Bao X; Yue Y; Schiff D; Bindra R; Li J
    Biomed Chromatogr; 2022 Dec; 36(12):e5478. PubMed ID: 35938683
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A new dried blood spot LC-MS/MS method for therapeutic drug monitoring of palbociclib, ribociclib, and letrozole in patients with cancer.
    Poetto AS; Posocco B; Gagno S; Orleni M; Zanchetta M; Iacuzzi V; Canil G; Buzzo M; Montico M; Guardascione M; Basile D; Pelizzari G; Alberti M; Gerratana L; Puglisi F; Toffoli G
    J Chromatogr B Analyt Technol Biomed Life Sci; 2021 Nov; 1185():122985. PubMed ID: 34700133
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Physiologically Based Pharmacokinetic Modeling of Central Nervous System Pharmacokinetics of CDK4/6 Inhibitors to Guide Selection of Drug and Dosing Regimen for Brain Cancer Treatment.
    Li J; Jiang J; Wu J; Bao X; Sanai N
    Clin Pharmacol Ther; 2021 Feb; 109(2):494-506. PubMed ID: 32799335
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A liquid chromatography with tandem mass spectrometry method for quantitating total and unbound ceritinib in patient plasma and brain tumor.
    Bao X; Wu J; Sanai N; Li J
    J Pharm Anal; 2018 Feb; 8(1):20-26. PubMed ID: 29568664
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quantification of Letrozole, Palbociclib, Ribociclib, Abemaciclib, and Metabolites in Volumetric Dried Blood Spots: Development and Validation of an LC-MS/MS Method for Therapeutic Drug Monitoring.
    Cecchin E; Orleni M; Gagno S; Montico M; Peruzzi E; Roncato R; Gerratana L; Corsetti S; Puglisi F; Toffoli G; Cecchin E; Posocco B
    Int J Mol Sci; 2024 Sep; 25(19):. PubMed ID: 39408783
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Simultaneous determination of flumatinib and its two major metabolites in plasma of chronic myelogenous leukemia patients by liquid chromatography-tandem mass spectrometry.
    Yang Y; Liu K; Zhong D; Chen X
    J Chromatogr B Analyt Technol Biomed Life Sci; 2012 May; 895-896():25-30. PubMed ID: 22472641
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumor pharmacokinetics and pharmacodynamics of the CDK4/6 inhibitor ribociclib in patients with recurrent glioblastoma.
    Miller TW; Traphagen NA; Li J; Lewis LD; Lopes B; Asthagiri A; Loomba J; De Jong J; Schiff D; Patel SH; Purow BW; Fadul CE
    J Neurooncol; 2019 Sep; 144(3):563-572. PubMed ID: 31399936
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quantitation of unbound sunitinib and its metabolite N-desethyl sunitinib (SU12662) in human plasma by equilibrium dialysis and liquid chromatography-tandem mass spectrometry: application to a pharmacokinetic study.
    Rais R; Zhao M; He P; Xu L; Deeken JF; Rudek MA
    Biomed Chromatogr; 2012 Nov; 26(11):1315-24. PubMed ID: 22259028
    [TBL] [Abstract][Full Text] [Related]  

  • 14. LC-MS/MS method for quantitation of the CK2 inhibitor silmitasertib (CX-4945) in human plasma, CSF, and brain tissue, and application to a clinical pharmacokinetic study in children with brain tumors.
    Zhong B; Campagne O; Salloum R; Purzner T; Stewart CF
    J Chromatogr B Analyt Technol Biomed Life Sci; 2020 Sep; 1152():122254. PubMed ID: 32615532
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Simple and rapid quantification of ribociclib in rat plasma by protein precipitation and LC-MS/MS: An application to pharmacokinetics of ribociclib nanoparticles in rats.
    Alshogran OY; Al-Shdefat R; Hailat M
    J Mass Spectrom; 2023 Dec; 58(12):e4984. PubMed ID: 37950646
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development and validation of a UPLC-MS/MS method for determination of motesanib in plasma: Application to metabolic stability and pharmacokinetic studies in rats.
    Ezzeldin E; Iqbal M; Al-Salahi R; El-Nahhas T
    J Pharm Biomed Anal; 2019 Mar; 166():244-251. PubMed ID: 30665192
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ribociclib (LEE011): Mechanism of Action and Clinical Impact of This Selective Cyclin-Dependent Kinase 4/6 Inhibitor in Various Solid Tumors.
    Tripathy D; Bardia A; Sellers WR
    Clin Cancer Res; 2017 Jul; 23(13):3251-3262. PubMed ID: 28351928
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development and validation of a sensitive liquid chromatography tandem mass spectrometry assay for the simultaneous determination of ten kinase inhibitors in human serum and plasma.
    Aghai F; Zimmermann S; Kurlbaum M; Jung P; Pelzer T; Klinker H; Isberner N; Scherf-Clavel O
    Anal Bioanal Chem; 2021 Jan; 413(2):599-612. PubMed ID: 33155133
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A validated LC-MS/MS method for determination of neuro-pharmacokinetic behavior of niraparib in brain tumor patients.
    Knight W; Margaryan T; Sanai N; Tovmasyan A
    J Pharm Biomed Anal; 2024 Aug; 245():116150. PubMed ID: 38657366
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasma pharmacokinetics and tissue distribution study of cajaninstilbene acid in rats by liquid chromatography with tandem mass spectrometry.
    Hua X; Fu YJ; Zu YG; Wu N; Kong Y; Li J; Peng X; Efferth T
    J Pharm Biomed Anal; 2010 Jun; 52(2):273-9. PubMed ID: 20116956
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.